US-China Biotech Transactions: Navigating Each Country’s Evolving Regulatory Landscape, Global Relay Intelligence & Practice

Partners Todd Liao and Carl Valenstein co-authored an article for Global Relay Intelligence & Practice discussing the rapidly evolving regulatory landscape governing US-China biotech transactions and the implications for cross-border dealmaking.

The authors examine parallel regulatory developments in the United States and China affecting outbound investment, licensing, and cross-border transaction structures. They also provide practical guidance for companies navigating increased scrutiny, emphasizing the importance of regulatory flexibility, early planning, and carefully evaluating transaction structures as both jurisdictions continue to refine their approaches.

Read the full Global Relay Intelligence & Practice article >>